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Abstract
Background: The risk of thrombus formation in the left atrium is known to be very high in 
patients with both mitral stenosis (MS) and atrial fibrillation (AF). However, that risk should 
not be ignored in patients with MS in sinus rhythm (SR). The aim of this study was to deter-
mine the clinical, echocardiographic, and biochemical factors that could have a determining 
role in the formation of a left atrial (LA) thrombus in patients with MS in SR.
Method: A total of 207 consecutive patients with MS who underwent both transthoracic 
echocardiography (TTE) and transesophageal echocardiography (TEE) for diagnosis or to 
investigate the presence of a thrombus in the LA and appendage were enrolled in this study.
Results: LA thrombus was detected in 21 of 207 patients. CHA2DS2-VASc score was not found 
to be a predictor of LA thrombosis in patients with MS in SR, despite the higher CHA2DS2- 
-VASc scores observed in those patients. The mitral valve area and mitral valve gradient were 
not predictive of LA thrombus development; however, LA anteroposterior diameter (LAAPD) 
was found to be a predictor of LA thrombosis. Levels of high sensitivity-C-reactive protein and 
uric acid were higher in the patients with LA thrombosis, but only uric acid was found to be  
a predictor of LA thrombosis in multivariate analysis.
Conclusions: A larger LAAPD and an elevated serum uric acid level were found to be independ-
ent predictors of LA thrombosis in patients with MS in SR. (Cardiol J 2015; 22, 3: 336–342)
Key words: mitral stenosis, sinus rhythm, left atrial thrombosis, uric acid, 
CHA2DS2-VASc score
Introduction
A thrombus within the left atrium (LA) is 
a common source of thromboemboli and it is fre-
quently seen in atrial fibrillation (AF) [1], valve 
disease [2, 3], and severe left ventricular systolic 
and diastolic dysfunction [4, 5]. The risk of throm-
bus formation in the LA is known to be very high 
in patients with both mitral stenosis (MS) and AF. 
However, the risk should not be ignored in patients 
with MS in sinus rhythm (SR). The prevalence of 
LA clots in patients with MS in SR was reported 
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as ranging from 2.4% to 13.5% in previous studies 
[6–10]. The pathophysiology of LA thrombosis in 
patients with MS includes mechanisms such as 
hypercoagulable conditions, blood stasis, inflam-
mation, and abnormal platelet size and activation 
[11–13].
Serum uric acid (SUA), which is the final prod-
uct of purine metabolism, has been associated with 
the pathophysiology of several diseases, including 
hypertension [14], chronic kidney disease [15], 
congestive heart failure [16], metabolic syndrome 
[17], type 2 diabetes mellitus [18], atherosclerosis 
with or without cardiovascular events [19–21], 
and stroke [22–23]. In addition, a correlation was 
recently detected between hyperuricemia and the 
development of new-onset AF and increased risk 
of ischemic stroke in patients with AF [24–27]. 
Previous studies suggested associations between 
hyperuricemia and endothelial dysfunction [28], 
local oxidant generation, and elevated circulating 
levels of systemic inflammatory mediators [29, 30].
The aim of the present study was to determine 
the clinical, echocardiographic, and biochemical 
factors that could play determining roles in the 
formation of LA thrombosis, and to investigate the 
relationship between SUA level and frequency of 
LA thrombosis in patients with MS in SR.
Methods
Patient selection
A total of 207 consecutive patients with MS 
(mitral valve area [MVA] < 1.5 cm2), who under-
went both transthoracic echocardiography (TTE) 
and transesophageal echocardiography (TEE) for 
diagnosis or to investigate the presence of a throm-
bus in the LA and appendage, were enrolled in this 
study. All patients had attended regular hospital 
appointments for at least 6 months and were in 
SR, as documented via electrocardiogram (ECG), 
at every control appointment and during TEE ex-
amination. Exclusion criteria included AF, no TEE, 
not presenting at regular visits for least 6 months, 
renal failure, acute rheumatic fever, acute infection, 
inflammatory disease, malignancy, and a history of 
anti-inflammatory, anticoagulant drug use.
Informed consent was obtained from all pa-
tients. This study complies with the Declaration 
of Helsinki, and the trial protocol was approved by 
the local Ethics Committee.
Blood sample
Blood samples were drawn from the antecu-
bital vein for determination of biochemical and 
hemostatic parameters after overnight fasting. 
EDTA tubes were used for automatic blood count. 
The blood counts were measured using an auto 
hematology analyzer (Mindray BC 5800, China, 
Mainland) per the manufacturer’s instructions. 
High-sensitivity C-reactive protein (hs-CRP) 
levels were immunologically determined using 
the immunoturbidimetric method (Abbott Aeroset 
1600 Autoanalyzer, Abbott Reagents, Germany). 
SUA levels were measured using an enzymatic 
colorimetric test on a Roche/Hitachi analyzer.
Echocardiographic assessment
Transthoracic 2-dimensional (2D) and Doppler 
echocardiographic assessments were performed 
using a Vivid S6 with a 3.5 MHz phased array 
transducer (GE Medical System, Horten, Norway). 
2D and pulsed wave Doppler echocardiographic 
studies were performed in the left lateral decubitus 
position with the conventional views (parasternal 
long- and short-axis, apical 4-chamber views). LA 
diameter, left ventricle (LV) end-diastolic diameter, 
and LV end-systolic diameter were measured by 
M-mode echocardiography. The LV ejection fraction 
(LVEF) was assessed from apical 2- and 4-chamber 
views, using the modified Simpson method. The 
MVA was measured using the planimetric method. 
The maximum velocity of tricuspid regurgitation 
was measured, and the pressure gradient was 
calculated. To estimate systolic pulmonary artery 
pressure, assumed right atrial pressure (10 mm 
Hg) was added to the gradient. M-mode measure-
ments and conventional Doppler echocardiographıc 
examinations were performed based on the criteria 
specified in the American and European Society of 
Echocardiography guidelines [31].
TEE was performed using a commercially 
available echocardiography machine (VIVID 6, GE 
Medical) with the use of a multiplane TEE probe 
and a 5 MHz phased array transducer. After admin-
istering topical anesthesia using lidocaine, the TEE 
probe was advanced and echocardiographic images 
were obtained. LA thrombus was diagnosed by 
the presence of a clearly defined echogenic intra-
cavitary mass with an echo texture different from 
that of the underlying endocardium and not due to 
the pectinate muscle. The presence or absence of 
a LA thrombus was evaluated independently by 
2 observers, and any discrepancy was resolved 
by consensus.
Statistical analysis
All analyses were performed using SPSS 
V 16.0 software for Windows (SPSS, Chicago, 
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Illinois). All data are presented as mean ± standard 
deviation unless otherwise stated. Comparison of 
parametric values between the two groups was 
performed by means of an independent sample 
t-test. Comparisons of nonparametric values be-
tween the two groups were performed by means 
of a Mann-Whitney U test. Categorical variables 
were compared by means of the c2 test. Pearson’s 
test was used to test the correlation of parametric 
variables, and Spearman’s test was used to test the 
nonparametric variables. Logistic regression analy-
sis was used to assess the predictors of LA throm-
bosis. Those variables with p < 0.1 by univariate 
analysis were included in the multivariate logistic 
regression analysis model and the respective odds 
ratios (OR) with 95% confidence intervals (CI) 
were calculated. All statistical tests were 2-sided 
and significance was determined at p < 0.05.
Results
The baseline characteristics of the study 
population are shown in Table 1. LA thrombus 
was found in 21 of the 207 patients. Patients with 
LA thrombosis were older than those without 
(49.9 ± 9.7 vs. 41 ± 8.7 years, respectively; p < 
< 0.001). Of the patients with LA thrombus, 55% 
were female compared to 81.8% of the patients 
without a thrombus (p = 0.009). The patients with 
LA thrombosis were more likely to have diabetes 
mellitus and a history of ischemic stroke (p = 0.03 
and p = 0.01, respectively). On investigation of 
clinical parameters, CHA2DS2-VASc (Congestive 
heart failure, Hypertension, Diabetes mellitus, 
age > 75 years; prior stroke or transient ischemic 
attack, Vascular disease, Age 65–74, female gen-
der) score was found to be significantly higher in 
patients with LA thrombosis (2.5 ± 1.5) than in 
the patients without a thrombus (1.4 ± 1.1; p = 
= 0.006). CHA2DS2-VASc score appeared to predict 
LA thrombosis on univariate analysis, but not on 
multivariate analysis (Tables 2, 3).
In terms of echocardiographic parameters, 
the LVEF values were lower in the patients with 
LA thrombosis compared to the patients without 
it (55.7 ± 7.6% vs. 61.4 ± 3.5%, respectively; 
p < 0.001). The LA anteroposterior dimension 
(LAAPD) values were greater in the patients with 
LA thrombosis compared to the patients without 
a thrombosis (5.2 ± 0.3 vs. 4.4 ± 0.4 cm, respective-
ly; p < 0.001). There was no significant difference 
in MVA between the thrombotic and non-thrombot-
ic patients (1 ± 0.1 vs. 1.1 ± 0.1 cm2, respectively; 
p = 0.07). However, mitral valve gradient values 
were higher in the patients with LA thrombosis 
compared to the non-thrombotic patients (14.9 ± 
± 4.4 vs. 10.9 ± 4.6 mm Hg, respectively; p < 0.001). 
The mean LA appendage filling velocities were 
Table 1. Demographic, clinical, echocardiographic and laboratory parameters of the study population.
Variable Thrombus (+) Thrombus (–) P 
Age [years] 49.9 ± 9.7 41 ± 8.7 < 0.001
Female gender 11 (55%) 153 (81.8%) 0.009
Diabetes mellitus 9 (45%) 42 (22.5%) 0.036
Hypertension 6 (30%) 54 (28.9%) 0.916
Ischemic stroke 3 3 0.015
LVEF 55.7 ± 7.6 61.4 ± 3.5 < 0.001
Left atrial diameter [cm] 5.2 ± 0.3 4.4 ± 0.4 < 0.001
Mitral valve area [cm2] 1 ± 0.1 1.1 ± 0.1 0.070
Mitral valve gradient [mm Hg] 14.9 ± 4.4 10.9 ± 4.6 < 0.001
Left atrial appendage velocity [cm/s] 16.3 ± 7.7 37.5 ± 12.1 < 0.001
Mean platelet volume [fL] 9.7 ± 1 8.5 ± 1.1 <0.001
Neutrophil/lymphocyte ratio 3.4 ± 0.8 2.1 ± 0.9 < 0.001
Uric acid [mg/dL] 9.1 ± 1.4 4.2 ± 1.8 < 0.001
Hs-CRP [mg/L] 2.6 ± 0.8 1.4 ± 0.5 < 0.001
Creatinine [mg/dL] 0.9 ± 1 0.9 ± 1.1 0.918
CHA2DS2-VASc 2.5 ± 1.5 1.4 ± 1.1 0.006
Hs-CRP — high sensitivity C-reactive protein; LVEF — left ventricular ejection fraction; CHA2DS2-VASc — Congestive heart failure, Hyper-
tension, diabetes mellitus, age > 75 years, prior stroke or transient ischemic attack, vascular disease, age 65–74, female gender
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16.3 ± 7.7 cm/s in patients with thrombosis 
compared to 37.5 ± 12.1 cm/s in those without 
a thrombus (p < 0.001). On univariate analysis, 
LAAPD and mean LA appendage filling velocities 
were found to be statistically significant predictors 
of thrombus development in SR. Nevertheless, 
on multivariate analysis, LAAPD was the only 
echocardiographic parameter that was found to be 
an independent predictor of LA thrombosis in the 
patients with MS in SR (OR 7.209, CI 1.073–48,452; 
p = 0.04) (Tables 2, 3).
On evaluation of the biochemical and hemo-
static parameters, mean platelet volume (MPV) 
was found to be significantly higher in the patients 
with LA thrombosis than in the patients without 
a thrombus (9.7 ± 1 vs. 8.5 ± 1.1 fL, respectively; 
p < 0.001). The hs-CRP levels were higher in 
the patients with a thrombus compared to those 
without a thrombus (2.6 ± 0.8 vs. 1.4 ± 0.5 mg/L, 
respectively; p < 0.001). SUA levels were also 
significantly higher in patients with LA thrombosis 
than without (9.1 ± 1.4 vs. 4.2 ± 1.8 mg/dL, respec-
tively; p < 0.001) (Fig. 1). In addition, there was 
a positive correlation between SUA and hs-CRP 
(r = 0.674; p < 0.001) (Fig. 2). In univariate analysis, 
the parameters that appeared to predict develop-
ment of thrombosis were hs-CRP, MPV, and uric 
acid. However, in multivariate analysis, only uric 
Table 3. Multivariate regression analysis for the investigation of independent correlates of left atrial 
thrombosis in the study population.
Variable Odds ratio Confidence interval P 
LVEF 0.913 0.759–1.098 0.332
Uric acid 2.497 1.132–5.510 0.023
Age 1.119 0.988–1.267 0.076
Female gender 5.665 0.453–70.796 0.178
Mean platelet volume 2.135 0.910–5.010 0.081
Hs-CRP 4.973 0.681–36.337 0.114
CHA2DS2-VASc 0.800 0.273–2.341 0.683
Left atrial diameter 7.209 1.073–48.452 0.042
Left atrial appendage velocity [cm/s] 0.906 0.792–1.036 0.148
Diabetes mellitus 0.089 0.006–1.383 0.084
Abbreviations as in Table 1.
Table 2. Odds ratio in univariate analysis.
Variable Odds ratio Confidence interval P 
Mitra valve gradient 2.126 0.746–6.763 0.638
LVEF 0.809 0.786–0.889 < 0.001
CHA2DS2-VASc 1.901 1.331–2.716 < 0.001
Mean platelet volume 2.606 1.668–4.073 < 0.001
Left atrial diameter 22.911 6.990–75.101 < 0.001
Left atrial appendage velocity [cm/s] 0,847 0.795–0.903 < 0.001
Uric acid 3.440 2.082–5.682 < 0.001
Hs-CRP 15.290 5.799–40.713 < 0.001
Mitral valve area 0.102 0.009–1.110 0.061
Diabetes mellitus 2.825 1.097–7271 0.031
Hypertension 0.985 0.363–2.673 0.977
Age 1.105 1.047–1.167 < 0.001
Female gender 3.375 1.317–8647 0.011
Abbreviations as in Table 1.
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acid was found to be a predictor of LA thrombosis 
development in the patients with MS in SR (OR 
2.497, CI 1.132–5.510; p = 0.02).
Discussion
In the present study, the predictors of LA 
thrombosis and the relationship between uric acid 
and LA thrombosis were investigated in patients 
with MS in SR. LAAPD and uric acid were found 
to be independent predictors of LA thrombosis in 
the patients with MS in SR.
Patients with AF are known to have a high 
incidence of LA thrombi. However, the incidence 
of LA thrombosis in patients with normal SR 
is not negligible. In a past study that assessed 
more than 20,000 patients in SR using TEE, the 
prevalence of LA thrombosis was approximately 
0.1% [32]. However, in the same study, patients 
who had high-risk factors, such as valve disease, 
LV systolic and diastolic dysfunction, or a history 
of AF, had a higher incidence of LA thrombosis. 
AF patients with severe MS have been shown to 
be at high risk for thromboemboli [33]. However, 
various studies have demonstrated that the risk 
of LA thrombosis in patients with MS in SR is still 
high. The prevalence of LA clots in patients with 
MS in SR was found to range from 2.4% to 13.5% 
in various studies [6–10]. The prevalence of LA 
clots was 13.5% in a study performed by Saidi et 
al. [8]. In another study that included 848 patients 
with MS in SR, the prevalence of LA clots was 
6.6% [34]. In the present study, the prevalence of 
LA thrombosis was 10.1%. Similar to the findings 
from a previous study [34], in the present study 
the patients with thrombi were older. Diabetes 
mellitus was more common in the patients with 
thrombi, but age and diabetes mellitus were not 
predictive of LA thrombosis development on 
multivariate analysis. Patients with MS in AF are 
known to have a high risk of thromboemboli, and 
there is no need to use CHA2DS2-VASc scores for 
risk evaluation in that patient population. How-
ever, no studies have been performed to evaluate 
the ability of the CHA2DS2-VASc score to predict 
LA thrombosis in patients with MS in SR. On 
evaluation of clinical parameters, CHA2DS2-VASc 
score was not found to be a predictor of LA throm-
bosis in patients with MS in SR, despite the higher 
CHA2DS2-VASc scores observed in patients with 
LA thrombi. Potentially, the lack of significance 
was due to the low CHA2DS2-VASc scores in our 
patient population.
Various studies with conflicting results have 
been performed to evaluate echocardiographic 
parameters in patients in SR. Some of the stud-
ies identified only the MVA as a predictor of LA 
thrombus formation [35, 36]. Kasliwal et al. [9] 
investigated the predictors of spontaneous echo 
contrast (SEC) in patients with MS and SR, and 
they demonstrated an association between SEC 
and smaller MVA, larger LA, and higher mean 
diastolic mitral pressure gradient. Nevertheless, 
in the study by Saidi et al. [8], which evaluated the 
relationship between echocardiographic param-
eters and LA thrombosis in patients with MS in SR, 
none of the parameters was found to be predictive 
of LA thrombosis. A recent study by Manjunath et 
al. [34], which included a larger patient group than 
Figure 1. Serum uric acid levels of patients with and 
without left atrial thrombosis.
Figure 2. Correlation graph of high sensitivity C-reactive 
protein (Hs-CRP) with uric acid.
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previous studies, reported a relationship between 
LA thrombosis and increasing age, anterosuperior 
LA dimension, and mean mitral valve gradient. In 
the present study, LA thrombus formation seemed 
to be associated with higher mean mitral valve 
gradient, smaller MVA, greater LAAPD, and de-
creased LA appendage filling velocity, but LAAPD 
was the only echocardiographic parameter found 
to be an independent predictor of LA thrombosis 
on multivariate analysis.
Previous studies have reported that patients 
with MS, with or without AF, have a hypercoagu-
lable condition [37]. Although intra-atrial stasis 
and low blood velocity are the major factors in LA 
thrombus formation, the pathophysiology of LA 
thrombosis and SEC occurring in patients with 
MS exhibits some other mechanisms, such as 
inflammation, abnormal platelet size and activa-
tion [1–13]. Some previous studies have shown 
that inflammation plays an important role in the 
formation of SEC and thromboemboli, and some in-
flammatory markers could be used as independent 
predictors for SEC and LA thrombosis in patients 
with MS. Karthikeyan et al. [38] demonstrated an 
association between LA thrombosis and elevated 
hs-CRP levels, independent of the severity of MS. 
Similarly, Kaya et al. [39] found increased hs-CRP 
level to be an independent risk factor of LA SEC 
in patients with MS. In the present study, hs-CRP 
level was also higher in patients with LA throm-
bosis and, in univariate analysis, hs-CRP levels 
appeared to predict the development of thrombi. 
However, in multivariate analysis, hs-CRP levels 
were not predictive of LA thrombus formation 
in the patients with MS in SR. The difference in 
the predictive quality of the hs-CRP levels in the 
present study may be related to the patient popula-
tion. While the above-mentioned studies included 
patients with MS in both AF and SR, the patient 
population in our study consisted only of patients 
with MS in SR.
Whether or not gout is present, elevated SUA 
level is associated with cardiovascular diseases 
such as hypertension [14], coronary heart disease 
[19–21], AF [24, 26], and stroke [22, 23]. Previous 
studies have suggested that this correlation could 
be due to endothelial dysfunction, local oxidant 
generation, elevated vascular smooth cell prolifera-
tion, and reduced vascular nitric oxide production 
induced by SUA [28–30]. Furthermore, a positive 
correlation has been demonstrated between SUA 
and elevated circulating levels of systemic inflam-
matory mediators, such as monocyte chemoattract-
ant protein-1, nuclear factor-kB, interleukin-1b, in-
terleukin-6, and tumor necrosis factor-a. Similarly 
[28–30], in the present study, a positive correlation 
between SUA and hs-CRP was also detected. Sev-
eral studies have detected a correlation between 
SUA and ischemic stroke [22, 23, 25]. Studies have 
suggested that SUA may have harmful effects on 
platelet function [40] and it may cause endothelial 
dysfunction [41], thereby explaining the relation-
ship. In addition, hyperuricemia was found to be 
correlated with LA dimension and a significant 
risk factor of new-onset AF [42]. In a recent study, 
hyperuricemia was associated with higher stroke 
rate in patients with AF, and even after CHA2DS2-
VASc score adjustment, hyperuricemia was found 
to be a significant risk factor for ischemic stroke 
[25]. No data on the association between SUA and 
LA thrombus in SR was found in the literature, and 
the present study was the first to investigate the 
relationship between SUA level and LA thrombo-
sis in patients with MS in SR. The SUA level was 
higher in patients with LA thrombosis, and the SUA 
level was found to be an independent predictor of 
the presence of LA thrombi.
As a limitation of this study, the possibility of 
intermittent AF, cannot be eliminated with 24 h of 
undergoing an ECG; however, the patients in this 
study were regularly evaluated with the standard 
12 lead ECG for at least 6 months.
Conclusions
In summary, patients in SR still have consider-
able risk for thromboemboli, and clinical, echocar-
diographic, and biochemical predictors are required 
when evaluating patients for risk stratification. 
In the present study, none of the clinical param-
eters were predictive of LA thrombus formation. 
However, larger LAAPD and elevated SUA levels 
were found to be independent predictors of LA 
thrombosis in patients with MS in SR.
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